| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Danshenxinkun B targets oxidative stress pathways and inflammatory mediators. As an antioxidant active ingredient, it functions by neutralizing reactive oxygen species and reducing oxidative damage to cells and tissues. The compound modulates inflammatory pathways, contributing to its anti-inflammatory properties. Its cardioprotective effects are mediated through improving blood flow and protecting against ischemia-related injury. The compound's mechanism of action involves the regulation of oxidative stress and inflammatory signaling pathways, although the specific molecular targets have not been fully elucidated. Based on its structural class as a diterpenoid quinone, it may interact with various cellular proteins involved in redox balance and inflammation.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Danshenxinkun B possesses significant antioxidant activity. It acts as a natural antioxidant with potential applications in foods and cosmetics. The compound's ability to scavenge free radicals and reduce oxidative stress makes it a valuable tool for studying oxidative damage and protection mechanisms. Its anti-inflammatory properties contribute to its potential in modulating inflammatory responses in various cell types. The compound's activity profile suggests that it may have cytoprotective effects against oxidative stress-induced cell damage. However, detailed in vitro potency data (e.g., IC₅₀ values) for specific assays are limited in the published literature.
|
| ln Vivo |
In vivo, Danshenxinkun B is expected to exhibit cardiovascular protective effects based on its traditional use in Danshen and its documented antioxidant and anti-inflammatory properties. It may improve blood flow and protect against ischemia-related injury. As a component of Salvia miltiorrhiza, which has been extensively studied in animal models of cardiovascular disease, Danshenxinkun B likely contributes to the overall cardioprotective effects of the herb. However, specific in vivo studies focusing exclusively on Danshenxinkun B are limited, and most research has been conducted on crude extracts or other major constituents of Danshen.
|
| Enzyme Assay |
In vitro non-cell enzyme/receptor binding assays for Danshenxinkun B typically involve antioxidant activity measurements using standard chemical assays such as DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging, ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging, or FRAP (ferric reducing antioxidant power) assays. The compound is incubated with the radical-generating system, and the decrease in absorbance is measured spectrophotometrically to calculate the scavenging activity and IC₅₀ values. These assays provide a quantitative measure of the compound's antioxidant capacity.
|
| Cell Assay |
In vitro cell-based assays for Danshenxinkun B typically use cell culture models of oxidative stress, such as endothelial cells, cardiomyocytes, or hepatocytes exposed to oxidative insults (e.g., H₂O₂, hypoxia-reoxygenation, or inflammatory cytokines). Cells are treated with Danshenxinkun B at various concentrations, and parameters such as cell viability (MTT or CCK-8 assays), reactive oxygen species levels (fluorescent probes such as DCFH-DA), antioxidant enzyme activities (SOD, CAT, GPx), lipid peroxidation (MDA), and inflammatory cytokine production (ELISA) are measured to evaluate cytoprotective and anti-inflammatory effects.
|
| Animal Protocol |
In vivo animal studies for Danshenxinkun B are limited. Standard protocols for evaluating cardiovascular protective compounds would involve oral or intraperitoneal administration of the compound to rodent models of myocardial ischemia-reperfusion injury, hypertension, or atherosclerosis. Parameters assessed would include infarct size, cardiac function (echocardiography), serum markers of cardiac injury (CK-MB, LDH, troponin), oxidative stress markers, inflammatory cytokines, and histopathological examination of cardiac tissues. However, specific published in vivo data for Danshenxinkun B are not well documented.
|
| ADME/Pharmacokinetics |
Danshenxinkun B has a molecular weight of 280.32 g/mol and a molecular formula of C₁₈H₁₆O₃. It is also known by the IUPAC name 1-hydroxy-8-methyl-2-propan-2-ylphenanthrene-3,4-dione. The compound should be stored at 2-8°C, protected from light. In solvent, it can be stored at -80°C for six months or at -20°C for one month. Detailed pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion have not been extensively characterized. As a diterpenoid quinone with moderate lipophilicity, it is expected to have reasonable membrane permeability and oral bioavailability.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Danshenxinkun B has not been comprehensively evaluated in published studies. As a natural component of Salvia miltiorrhiza, which has a long history of safe use in traditional medicine, it is generally considered to have low toxicity at therapeutic doses. The compound is classified as a research reagent and is not intended for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicological studies, including acute, subchronic, and chronic toxicity assessments, have not been reported.
|
| References | |
| Additional Infomation |
Danshenxinkun B has been reported to exist in Danshen, Mucinous Danshen, and other organisms with available data.
Danshenxinkun B is a bioactive diterpenoid quinone isolated from Salvia miltiorrhiza (Danshen), a traditional Chinese medicinal herb. It is also known as 丹参新醌B in Chinese. The compound exhibits antioxidant, anti-inflammatory, and cardioprotective properties. It is primarily applied in pharmacological studies, cardiovascular research, and drug discovery efforts targeting oxidative and inflammatory pathways. The compound is also known by the synonym 1-hydroxy-8-methyl-2-propan-2-ylphenanthrene-3,4-dione. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C18H16O3
|
|---|---|
| Molecular Weight |
280.3178
|
| Exact Mass |
280.11
|
| CAS # |
65907-76-8
|
| PubChem CID |
5320113
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.285±0.06 g/cm3
|
| Boiling Point |
465.2±45.0 °C at 760 mmHg
|
| LogP |
3.838
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PVIJIAVGFMTLEI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O3/c1-9(2)14-16(19)13-8-7-11-10(3)5-4-6-12(11)15(13)18(21)17(14)20/h4-9,19H,1-3H3
|
| Chemical Name |
1-hydroxy-8-methyl-2-propan-2-ylphenanthrene-3,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL | |
| 5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL | |
| 10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
